Literature DB >> 11463410

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

M Martin1, T F Tsai, B Cropp, G J Chang, D A Holmes, J Tseng, W Shieh, S R Zaki, I Al-Sanouri, A F Cutrona, G Ray, L H Weld, M S Cetron.   

Abstract

BACKGROUND: In 1998, the US Centers for Disease Control and Prevention was notified of three patients who developed severe illnesses days after yellow fever vaccination. A similar case occurred in 1996. All four patients were more than 63 years old.
METHODS: Vaccine strains of yellow fever virus, isolated from the plasma of two patients and the cerebrospinal fluid of one, were characterised by genomic sequencing. Clinical samples were subjected to neutralisation assays, and an immunohistochemical analysis was done on one sample of liver obtained at biopsy.
FINDINGS: The clinical presentations were characterised by fever, myalgia, headache, and confusion, followed by severe multisystemic illnesses. Three patients died. Vaccine-related variants of yellow fever virus were found in plasma and cerebrospinal fluid of one vaccinee. The convalescent serum samples of two vaccinees showed antibody responses of at least 1:10240. Immunohistochemical assay of liver tissue showed yellow fever antigen in the Kuppfer cells of the liver sample.
INTERPRETATION: The clinical features, their temporal association with vaccination, recovery of vaccine-related virus, antibody responses, and immunohistochemical assay collectively suggest a possible causal relation between the illnesses and yellow fever vaccination. Yellow fever remains an important cause of illness and death in South America and Africa; hence, vaccination should be maintained until the frequency of these events is quantified.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463410     DOI: 10.1016/s0140-6736(01)05327-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  55 in total

1.  Yellow fever vaccine.

Authors:  Philip P Mortimer
Journal:  BMJ       Date:  2002-02-23

2.  Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles.

Authors:  Beate M Kümmerer; Charles M Rice
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

4.  Molecular characterization of a hamster viscerotropic strain of yellow fever virus.

Authors:  Monica A McArthur; Miguel T Suderman; John-Paul Mutebi; Shu-Yuan Xiao; Alan D T Barrett
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 5.  Recent developments: Travel medicine.

Authors:  Jane N Zuckerman
Journal:  BMJ       Date:  2002-08-03

6.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

7.  A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Authors:  Richard W Douce; Diana Freire; Betzabe Tello; Gavino A Vásquez
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

8.  A global perspective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety.

Authors:  Peter I Folb; Ewa Bernatowska; Robert Chen; John Clemens; Alex N O Dodoo; Susan S Ellenberg; C Patrick Farrington; T Jacob John; Paul-Henri Lambert; Noni E Macdonald; Elizabeth Miller; David Salisbury; Heinz-J Schmitt; Claire-Anne Siegrist; Omala Wimalaratne
Journal:  Am J Public Health       Date:  2004-11       Impact factor: 9.308

9.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.